Is GERON CORP (GERN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 12.5% / 30% | 36.6% / 30% | 4.0% / 30% | 9.85% / 5% | ✗ NOT HALAL |
| DJIM | 12.5% / 33% | 36.6% / 33% | 4.0% / 33% | 9.85% / 5% | ✗ NOT HALAL |
| MSCI | 21.4% / 33% | 62.7% / 33% | 6.9% / 33% | 9.85% / 5% | ✗ NOT HALAL |
| S&P | 12.5% / 33% | 36.6% / 33% | 4.0% / 33% | 9.85% / 5% | ✗ NOT HALAL |
| FTSE | 21.4% / 33% | 62.7% / 33% | 6.9% / 50% | 9.85% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 97.4% | |
| Operating Margin | -17.7% | |
| Net Margin | -45.4% | |
| Return on Equity (ROE) | -33.0% | |
| Return on Assets (ROA) | -5.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$111M |
| Free Cash Flow | -$111M |
| Total Debt | $122M |
| Debt-to-Equity | 54.0 |
| Current Ratio | 4.7 |
| Total Assets | $571M |
Price & Trading
| Last Close | $1.54 |
| 50-Day MA | $1.55 |
| 200-Day MA | $1.37 |
| Avg Volume | 15.0M |
| Beta | 0.6 |
|
52-Week Range
$1.04
| |
About GERON CORP (GERN)
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is GERON CORP (GERN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), GERON CORP is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is GERON CORP's debt ratio?
GERON CORP's debt ratio is 12.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 21.4%.
What are GERON CORP's key financial metrics?
GERON CORP has a market capitalization of $897M, and revenue of $184M. The company maintains a gross margin of 97.4% and a net margin of -45.4%. Return on equity stands at -33.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.